Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CPMVNASDAQ:EDSAOTCMKTS:NVLNFNYSEMKT:PHGE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPMVMosaic ImmunoEngineering$0.27-48.5%$0.68$0.10▼$1.13$1.97M0.111,009 shs223 shsEDSAEdesa Biotech$1.99-1.0%$2.26$1.55▼$5.59$13.98M0.55488,511 shs23,710 shsNVLNFNovelion Therapeutics$0.70-1.2%$0.70$0.51▼$1.00$13.77M2.15261,364 shs26,900 shsPHGEBiomX$0.50-32.6%$0.56$0.48▼$4.90$13.58M1.5181,541 shs53,300 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPMVMosaic ImmunoEngineering+7.80%-2.22%-18.77%-46.12%+25.36%EDSAEdesa Biotech+2.55%-0.99%-14.83%-10.43%-54.11%NVLNFNovelion Therapeutics0.00%0.00%0.00%0.00%0.00%PHGEBiomX-1.75%-6.84%-16.28%-35.30%-85.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPMVMosaic ImmunoEngineering0.6682 of 5 stars0.03.00.00.02.81.70.0EDSAEdesa Biotech2.5543 of 5 stars3.55.00.00.00.81.70.6NVLNFNovelion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APHGEBiomX2.0981 of 5 stars3.50.00.00.02.00.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPMVMosaic ImmunoEngineering 0.00N/AN/AN/AEDSAEdesa Biotech 3.00Buy$21.00955.28% UpsideNVLNFNovelion Therapeutics 0.00N/AN/AN/APHGEBiomX 3.00Buy$21.004,116.87% UpsideCurrent Analyst Ratings BreakdownLatest CPMV, PHGE, NVLNF, and EDSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/4/2025PHGEBiomXHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.003/13/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPMVMosaic ImmunoEngineeringN/AN/AN/AN/A($0.81) per shareN/AEDSAEdesa BiotechN/AN/AN/AN/A$0.18 per shareN/ANVLNFNovelion Therapeutics$130.43M0.11N/AN/A($4.69) per share-0.15PHGEBiomXN/AN/AN/AN/A$0.70 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPMVMosaic ImmunoEngineering-$1.01M-$0.12N/A∞N/AN/AN/A-1,371.05%8/12/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-233.69%-124.14%8/8/2025 (Estimated)NVLNFNovelion Therapeutics-$108.33MN/A0.00∞N/AN/AN/AN/AN/APHGEBiomX-$28.32M-$0.85N/AN/AN/AN/A-127.82%-56.50%N/ALatest CPMV, PHGE, NVLNF, and EDSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/20/2025Q1 2025CPMVMosaic ImmunoEngineeringN/A-$0.03N/A-$0.03N/AN/A5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A4/15/2025Q4 2024CPMVMosaic ImmunoEngineeringN/A-$0.02N/A-$0.02N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPMVMosaic ImmunoEngineeringN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/ANVLNFNovelion TherapeuticsN/AN/AN/AN/AN/APHGEBiomXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPMVMosaic ImmunoEngineeringN/A0.010.01EDSAEdesa BiotechN/A1.090.91NVLNFNovelion TherapeuticsN/AN/AN/APHGEBiomX0.512.842.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPMVMosaic ImmunoEngineeringN/AEDSAEdesa Biotech5.50%NVLNFNovelion Therapeutics48.64%PHGEBiomX40.57%Insider OwnershipCompanyInsider OwnershipCPMVMosaic ImmunoEngineering80.99%EDSAEdesa Biotech22.60%NVLNFNovelion Therapeutics3.60%PHGEBiomX1.17%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPMVMosaic ImmunoEngineering37.24 million1.38 millionNot OptionableEDSAEdesa Biotech207.02 million2.60 millionNot OptionableNVLNFNovelion Therapeutics10919.62 millionN/ANot OptionablePHGEBiomX12026.18 million44.04 millionNot OptionableCPMV, PHGE, NVLNF, and EDSA HeadlinesRecent News About These CompaniesBiomX Inc. to Present Positive Phase 2 Results for BX211 at Biomed Israel 2025 ConferenceMay 21, 2025 | nasdaq.comBiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 ConferenceMay 19, 2025 | globenewswire.comBiomX Inc. (AMEX:PHGE) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comBiomX Inc. (PHGE) Q1 2025 Earnings Conference Call TranscriptMay 15, 2025 | seekingalpha.comBiomX Reports First Quarter 2025 Financial Results and Provides Business and Program UpdatesMay 15, 2025 | globenewswire.comBiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025May 8, 2025 | globenewswire.comBiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowApril 18, 2025 | zacks.comBiomX announces going concern qualification from independent auditApril 1, 2025 | markets.businessinsider.comBiomX target adjusted to $21 from $2 at H.C. WainwrightApril 1, 2025 | markets.businessinsider.comBiomX Announces Compliance with NYSE Guidelines on Audit Opinion DisclosureApril 1, 2025 | globenewswire.comBiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)March 31, 2025 | globenewswire.comBiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program UpdatesMarch 25, 2025 | globenewswire.comBiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025March 19, 2025 | globenewswire.comBiomX reports “impressive” data in first bacteriophage trialFebruary 21, 2025 | pharmaphorum.comBiomX regains compliance with NYSE American continued listing standardsDecember 17, 2024 | markets.businessinsider.comBiomX shares hold Buy rating from H.C. Wainwright on Q3 resultsNovember 17, 2024 | uk.investing.comBiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program UpdatesNovember 14, 2024 | globenewswire.comBiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024November 12, 2024 | globenewswire.comBiomX Announces a Mandatory Unit SeparationOctober 15, 2024 | globenewswire.comBiomX Stock Gains From Favorable Study Data Presentation on BX004September 20, 2024 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCPMV, PHGE, NVLNF, and EDSA Company DescriptionsMosaic ImmunoEngineering OTCMKTS:CPMV$0.27 -0.26 (-48.48%) As of 03:10 PM EasternMosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.Edesa Biotech NASDAQ:EDSA$1.99 -0.02 (-1.00%) Closing price 03:56 PM EasternExtended Trading$2.01 +0.02 (+0.95%) As of 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Novelion Therapeutics OTCMKTS:NVLNF$0.70 -0.01 (-1.20%) As of 01/16/2020Novelion Therapeutics Inc., a biopharmaceutical company, develops therapies for individuals living with rare diseases in the United States, Japan, Brazil, and internationally. Its commercial products include metreleptin, a recombinant analog of human leptin, which is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy under the MYALEPTA brand name; and lomitapide capsule for the treatment of adult patients with homozygous familial hypercholesterolemia under the JUXTAPID and LOJUXTA brands. The company was formerly known as QLT Inc. and changed its name to Novelion Therapeutics Inc. in November 2016. Novelion Therapeutics Inc. was founded in 1981 and is headquartered in Vancouver, Canada.BiomX NYSEMKT:PHGE$0.50 -0.24 (-32.61%) Closing price 03:58 PM EasternExtended Trading$0.50 +0.00 (+0.20%) As of 06:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings ThredUp Stock Reverses on AI Buzz, Eyes Double-Digit Gains Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
